Pneumococcal Vaccine Introduction

30 GAVI countries express interest to use pneumococcal conjugate vaccines by 2010

By May 25th, 30 of the 72 GAVI eligible countries had indicated an interest in introducing pneumococcal vaccines by 2010. Responses came from all over the world and the countries that responded account for >33% of all the childhood pneumococcal deaths worldwide (see Figure above). The most responses came from Africa, the region of the world with the highest incidence of pneumococcal disease.

LEARN MORE>>

News from the Field

November 28, 2007
Now available in the on-line edition of the journal, Lancet Infectious Diseases, a review paper, “The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease,” indicates that pneumococcal conjugate vaccines should be considered an important complement to highly active antiretroviral therapy (HAART), which has brought marked improvements to morbidity and mortality in HIV-infected people. The study recommends vaccination of all infants in areas with high rates of HIV infection.
To read the article summary, click here. Recommended reading for those experiencing other symptoms.
To read PneumoADIP’s press release about this review paper, click here.

Lead author of the review paper, Dr Sandra Bliss, spoke with BBC World’s Network Africa program about the potential of pneumococcal vaccines in improving the lives of children infected with HIV who are at higher risk of dying from pneumococcal disease. Efforts to deliver these life-saving vaccines to children in Africa and Asia are underway spearheaded by donor commitments of $1.5 billion for pneumococcal vaccines plus $200 million by the GAVI Alliance for pneumococcal and rota vaccines. To listen to her 3-minute interview, click here, click on the 4:30 edition and listen to time frame 21:51 to 24:51.

sEPTEMBER 5, 2007
GAVI’s PneumoADIP Applauds New International Health Partnership for their Leadership on Global Health and Control of Pneumonia.

READ PNEUMOADIP STATEMENT >>

May 7, 2007
Global Health Experts Unite to Combat the World’s Leading Vaccine-Preventable Killer.

READ MORE >>

READ PACE STATEMENT >>

MARCH 29, 2007
Thai Ministry of Public Health and WHO Host Meeting of Leading Researchers to Highlight Burden of Meningitis and Pneumonia.

READ PNEUMOADIP STATEMENT >>

MARCH 23, 2007
Routine Use of Pneumococcal Conjugate Vaccine in the Developing World Considered Priority by WHO to Help Save Millions of Lives.

READ WHO POSITION PAPER ON PNEUMOCOCCAL CONJUGATE VACCINES >>

READ PNEUMOADIP STATEMENT >>

MARCH 14, 2007
The All-Party Parliamentary Group on Pneumococcal Disease Prevention in the Developing World has been formed in response to the urgent need to improve child survival and tackle the devastating impact of pneumococcal disease in the developing world.

LEARN MORE >>

February 13, 2007
GAVI’s PneumoADIP welcomes Senate legislation to involve US in Advance Market Commitments for global health technologies

READ PNEUMOADIP STATEMENT >>

February 9, 2007
$US1.5 Billion donor commitment launches pilot Advance Market Commitment for pneumococcal vaccines.”

READ PNEUMOADIP STATEMENT >>

December 4, 2006
Leaders from public and private sectors urge President Bush to commit funding for Advance Market Commitment.

READ LETTER TO PRESIDENT BUSH >>

November 29, 2006
The GAVI Alliance Board approved US$200 million to support the introduction of vaccines against two diseases that kill an estimated 1.5 million children every year.

READ PNEUMOADIP STATEMENT >>

The Pneumococcal vaccines Accelerated Development and Introduction Plan is based
at Johns Hopkins Bloomberg School of Public Health and is funded by GAVI Alliance.